

(ShareCast News) - Shire announced the US launch of Vonvendi on Tuesday, which is the only recombinant treatment for adults living with von Willebrand...


(ShareCast News) - First-half results from Shire confirmed the drugmaker's strong performance so far in 2016, completing two acquisitions and continui...


(ShareCast News) - Next: Goldman Sachs reiterates sell with a target price of 4800p. Standard Chartered: JP Morgan maintains overweight with a 800p ta...


(ShareCast News) - Laird: UBS upgrades to buy with a target price of 350p. Direct Line Group: Deutsche Bank maintains buy with a 435p target. Associa...


* Q2 sales rise by a better-than-expected 57 pct * Upgrades annual Baxalta synergy targets to $700 mln * Raises full-year EPS guidance * Shares up 3 p...


(ShareCast News) - Shire has upgraded its full year guidance and upped its interim dividend after it enjoyed a strong performance in the first half of...


LONDON, Aug 2 (Reuters) - Drugmaker Shire upgraded its guidance for 2016 on Tuesday, after it hiked the predicted cost saving target for its $32 billi...